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We examined the effects of post-ischemic blockade of angiotensin AT1 receptors by candesartan 
on cerebral infarction and formation of edema. Male Sprague–Dawley rats were divided into three 
groups, sham, control ischemic, and candesartan-treated (0.3 mg/kg) ischemic. Transient focal cerebral 
ischemia was induced by 90-min-long occlusion of the left middle cerebral artery followed by 24-h-long 
reperfusion. Neurological deficit score was evaluated at the end of the reperfusion period. Thereafter, 
the animals were randomly selected and used for three projects: (i) Measurement of the infarct volumes, 
(ii) investigation of ischemic brain edema formation using a wet/dry method, and (iii) assessment of 
the malondialdehyde (MDA) and reduced glutathione (GSH) concentrations using a HPLC technique. 
Induction of cerebral ischemia in the control group produced considerable infarctions in the cortex and 
striatum in conjunction with severely impaired motor functions. Candesartan treatment significantly 
reduced the infarct volumes and improved the above functions. The water content in the left (lesioned) 
hemisphere was considerably elevated in the control ischemic group. Candesartan treatment significantly 
lowered the water content in the ischemic lesioned hemisphere, retained tissue GSH level, and led to 
a lower MDA production. AT1 receptor blockade by candesartan treatment can noticeably decrease 
ischemic brain injury and attenuate edema formation, likely via increasing the antioxidant activity. 
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INTRODUCTION
With an around 30% mortality rate, stroke remains 
the third leading cause of death in industrialized 
countries. Ischemic brain injury results from a 
complex sequence of pathophysiological events 
developing over time and space [1]. The extent of 
the tissue damage depends on both intensity and 
duration of focal cerebral ischemia [2]. Ischemic 
brain edema is a life-threatening complication of 
cerebral infarction that significantly aggravates the 
primary ischemic injury of the brain [3] via increased 
intracranial pressure and herniation [1]. Therefore, 
prevention from the development of brain edema 
may decrease cerebral injury and reduce stroke-
related mortality.
Experimental and clinical studies allowed 
researchers to suggest that inhibition of the renin-
angiotensin system (RAS) by inactivation of 
ACE or angiotensin 1 (AT1) receptors might be 
effective not only in reducing the occurrence of 
stroke, but also may attenuate neuronal injury [4]. 
Furthermore, long-term pretreatment with ACE 
inhibitors or AT1 receptor blockers was reported 
to prevent the occurrence of cerebral ischemia in 
stroke-prone spontaneously hypertensive rats [5-7]. 
Other reports also indicated that inhibition of ACE 
[8] or AT1 receptors [9] prior to the induction of 
ischemia improve neurological recovery from 
cerebral ischemia. There are a few studies of the 
effects of post-ischemic AT1 receptor blockade on 
brain ischemic/reperfusion (I/R) injuries and their 
mechanisms.
Oxygen free radicals may play a noticeable 
role in brain I/R injuries. The amount of oxygen 
provided during reperfusion exceeds the capabilities 
of mitochondrial utilization. Therefore, a shift 
towards high production of free radical-related 
compounds, such as NO, superoxide, hydrogen 
peroxide, and hydroxyl, is formed [10]. These 
agents are constantly scavenged by superoxide 
dismutase, glutathione peroxidase, and catalase. 
Other antioxidants, including reduced glutathione 
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(GSH), ascorbic acid, and vitamin E, are also 
likely to be involved in detoxification of the free 
radicals. When endogenous antioxidant mechanisms 
are suppressed or the production of free radicals 
outweighs these mechanisms, a chain of reactions 
(denaturation of proteins, inactivation of enzymes, 
and breaking down of carbohydrates) starts. This 
leads to intense lipid peroxidation in the inner and 
outer mitochondrial and cell membranes [11].
As the RAS and inflammatory responses play 
important roles in I/R injuries, our study was 
designed to evaluate the neuroprotective effects of 
post-ischemic treatment with candesartan, an AT1 
receptor antagonist, and the mechanisms of these 
effects.
METHODS
Fifty-four male Sprague-Dawley rats (280-320 g) 
were obtained from the Central animal house 
facility of the Ardabil University of Medical 
Sciences (Ardabil, Iran). Anesthesia was made by 
i.p. injections of chloral hydrate (400 mg/kg). Body 
temperature was maintained at 37 ± 0.5°C with a 
heating feedback control system. 
Laser Doppler Flowmetery. Regional cerebral 
blood flow (rCBF) was monitored in the cerebral 
cortex of the left hemisphere within the territory 
supplied by the middle cerebral artery (MCA) using 
a laser Doppler flowmeter pencil probe (MNP100, 
AD Instrument, Australia). Following dissection of 
the left m. temporalis between the eye and the ear, a 
burr hole was drilled 5 mm lateral and 1 mm posterior 
to the bregma [12]. To prevent displacement of the 
probe, rCBF was continuously measured from before 
MCA occlusion, during such occlusion, and during 
the first 10 min of reperfusion time. Baseline CBF 
values measured before occlusion were defined as 
100%. Occlusion of the MCA was documented by 
the decrease in laser Doppler signals to lower than 
20% of the baseline.
Experimental Protocol. Effects of post-
ischemic candesartan treatment on brain injury and 
neurological score were investigated in the following 
randomly divided three groups of animals: group 1 
(sham group, n = 6), rats underwent surgery at the 
neck region with no occlusion of the MCA, group 
2 (control ischemic group, n = 6), rats experienced 
brain ischemia by 90-min-long MCA occlusion 
followed by 24-h-long reperfusion and received the 
vehicle (normal saline, 1 ml/kg) at the beginning 
of the reperfusion period, and group 3 (candesartan 
post-treated ischemic group, n = 6), rats experienced 
ischemia and reperfusion similarly to group 2, but 
received i.p. injections of candesartan (0.3 mg/kg, 
LKT laboratories, USA) at the beginning of 
reperfusion. 
Assessment of the effects of post-ischemic 
candesartan treatment on the formation of brain 
edema and measurement of the level of tissue 
malondialdehyde (MDA) as a marker of lipid 
peroxidation and that of tissue reduced glutathione 
(GSH) as a marker of the antioxidant capacity were 
done in another six parallel groups (n = 6 in each) of 
animals under the same conditions as in groups 1-3. 
Induction of Transient Focal Cerebral 
Ischemia. Ninety-minute-long occlusion of the 
MCA and 24-h-long reperfusion of the left cerebral 
hemisphere were carried out using an intraluminal 
filament method described by Longa et al. [13] 
and modified by Panahpour et al. [14]. Briefly, the 
left common carotid artery was exposed through 
a midline neck incision. Through this artery, a 
surgical nylon silicone-coated thread (4-0 Ethilon) 
was placed into the internal carotid artery and gently 
advanced up until seeing a sharp decline in the blood 
flow trace is seen. Occlusion was terminated by 
gently pulling out the thread. After re-establishment 
of the blood flow, all the incisions were sutured; 
the animals were allowed to recover from anesthesia 
and returned to a warm cage for recuperation during 
the 24-h-long reperfusion period. 
Behavioral tests were performed by a blinded 
observer 24 h after surgery in the sham group or 24 h 
after MCA occlusion in the ischemic groups. As was 
described previously, the five-point scale grading 
neurological deficit score (NDS) test was carried 
out to evaluate the neurological outcome [14]. Rats 
with normal motor function were graded 1. Rats 
with contralateral flexion of the body or forelimb 
upon lifting by the tail were graded 2. Grade 3 was 
assigned to dysfunctional rats circling to the side 
contralateral with respect to occlusion. Grade 4 was 
assigned to rats with loss of the righting reflex and 
decreased resistance to lateral push; finally, grade 
5 characterized rats having no spontaneous motor 
activity. After the NDS test, animals were sacrificed 
under deep anesthesia; the brain was removed, 
cleaned, and solidified by immersion in cold saline 
(4°C). Frontal 2-mm-thick slices were prepared using 
a brain matrix and stained with triphenyltetrazolium 
chloride (TTC), as was described previously 
[14, 15]. After staining, the slice images were 
digitized using a Cannon camera, and the cerebral 
infarction areas were measured with computer-
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based NIH image analyzer software [14, 15]. 
Ischemic brain edema was assessed using a dry/
wet method according to the technique presented 
by Gerriets et al. [16]. The normalized brain water 
content (WC) for each hemisphere was calculated 
by measuring the wet weight (WW) and dry weight 
(DW) of the ipsilateral (lesioned) and contralateral 
(non-lesioned) hemispheres by the following 
equation:
WC (%) = [(WW – DW)/WW] ∙ 100%.
Preparation of Tissue Samples. Twenty-four 
hours after the beginning of reperfusion, the animals 
were decapitated. The brain was removed, and the 
ischemic area (core and penumbra regions) of the 
ipsilateral hemisphere was dissected according to 
the well-known protocols for rodent models with 
unilateral MCA occlusion [17, 18]. Briefly, the 
brain was sectioned into three slices beginning 
3 mm from the anterior tip of the frontal lobe. 
In section 2 (4 mm thick), the ischemic area was 
dissected with a longitudinal cut approximately 
2 mm from the midline. The tissue was weighed and 
homogenized in PBS with a weight-to-volume ratio 
1:5. The homogenate was centrifuged (10,000g, 
4°C) for 30 min. The supernatants for each sample 
were separated in Eppendorf tubes and kept at 
–80°C until analysis.
Estimation of Lipid Peroxidation. Lipid 
peroxidation was evaluated by measuring the 
MDA concentration in brain samples. The MDA 
levels were measured using a high-performance 
liquid chromatography (HPLC) method [19] with 
some modifications. Briefly, a 100 ml aliquot of 
the supernatant was placed in a 1.5-ml Eppendorf 
tube, and 50 ml of 6 M NaOH was added. Alkaline 
hydrolysis of protein-bound MDA was achieved by 
incubating this mixture in a 60°C water bath for 
30 min. Then, protein was precipitated with 50 ml 
of 35% (v/v) perchloric acid, and the mixture was 
centrifuged at 2,800g for 10 min. A 100 ml volume 
of the supernatant was transferred to an Eppendorf 
tube and mixed with 10 ml 2,4-nitrophenylhydrazine 
(DNPH) prepared as a 5 mM solution in 2 M 
hydrochloric acid. Finally, this reaction mixture was 
incubated for 30 min at room temperature (protected 
from light). A 50 ml aliquot of the reaction mixture 
was injected into the HPLC system equipped with 
a C18 column (4.6´250 mm, 5 µm particle size). 
Results were expressed in nanomoles per one 
milligram of wet tissue weight.
Estimation of GSH. The concentration of reduced 
GSH as an important biomarker of the antioxidant 
defense capacity was also measured using the 
HPLC method [20] with some modifications. 
Briefly, a 100 ml volume of the sample supernatant 
was placed in an Eppendorf vial and diluted with 
an equal volume of trichloroacetic acid (5% final 
concentration w/v) and centrifuged at 10,000g 
for 15 min. A 100 ml volume of the supernatant 
was transferred to a new Eppendorf vial. After 
alkalization, the sample was reacted with an equal 
volume of 2,4-dinintrofluorobenzene solution 
(1.5% in ethanol v/v) for 1 h at room temperature in 
the dark. After acidification with 10 ml HCl (37% 
initial concentration v/v), 50 ml of the sample was 
loaded onto the HPLC. Results were expressed in 
millimoles per one milligram of wet tissue weight.
Statistical Analysis. Numerical values are 
expressed as means ± s.e.m. The independent t-test 
and one-way ANOVA with the post-hoc Holm-Sidak 
test were used for comparisons. The statistical 
significance was accepted at P < 0.05.
RESULTS
Cerebral Blood Flow Recording. The rCBF 
value was reduced to less than 20% baseline in the 
control and candesartan-treated ischemic groups 
after MCA occlusion. There was no significant 
difference between rCBF values in the groups 
during occlusion and the first 10 min of reperfusion 
(Fig. 1).
Evaluation of NDS. The mean NDS of control 
ischemic rats (4.3 ± 0.6) was dramatically higher 
than that of sham-operated rats (1.00; P < 0.01). 
The NDS of ischemic rats receiving 0.3 mg/kg 
candesartan post-ischemically (1.67 ± 0.2) was 
significantly lower (less than 40%) than that of 
control ischemic rats (P < 0.05).
Assessment of the Cerebral Infarct Volumes. 
Sham-operated rats had no infarctions. The total 
infarct volume in ischemic rats receiving 0.3 mg/kg 
candesartan was significantly smaller than that in 
control ischemic rats (P < 0.01). When compared 
to control ischemic animals, candesartan-treated 
ischemic rats had significantly smaller cortical and 
striatal infarct volumes (P < 0.05; Fig. 2).
Assessment of Ischemic Brain Edema. There 
was no statistically significant difference between 
the right-side water content in the brains of animals 
of the experimental groups. Moreover, there was 
no significant difference between the left-side and 
right-side water contents in the brains of sham-
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operated rats. The left (ischemic)-side brain water 
content of control ischemic rats (83.1 ± 0.46%) was 
significantly greater than that in sham-operated rats 
(P < 0.01). Post-ischemic treatment with candesartan 
(0.3 mg/kg) was associated significantly with the 
lower left-side brain water content (80.9 ± 0.81%) 
than that in control ischemic rats (81.6 ± 0.45%, 
P < 0.05; Fig. 3). 
Assessment of MDA and GSH. Ninety-minute-
long ischemia and 24-h-long reperfusion in the 
control ischemic group resulted in significantly 
reduced GSH and increased MDA concentrations in 
the left side of the brain tissue, as compared to the 
sham group (P < 0.01). Post-ischemic candesartan 
treatment provided a significantly increased GSH 
concentration and a reduced MDA concentration, as 
compared to the corresponding figures in the control 
ischemic group (P < 0.05, Figs. 4 and 5).
DISCUSSION
The renin-angiotensin system has been shown 
to significantly participate in the pathogenesis 
of ischemic events, including stroke [4, 21, 22]. 
Most of the actions of Ang II are mediated through 
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Fig. 1. Normalized values of regional cerebral blood flow in control ischemic rats (filled columns, n = 5) and ischemic rats that 
received 0.3 mg/kg candesartan (dashed columns, n = 5) during occlusion of the middle cerebral artery (MCAO) and at the beginning 
of reperfusion (REP). 
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Fig. 2. Total, cortical, and subcortical infarct volumes, mm3, 
in control ischemic rats and ischemic rats that received 
candesartan at the beginning of reperfusion (filled and dashed 
columns, respectively). Asterisks indicate significant differences 
(P < 0.05) from control rats.
Fig. 3. Normalized values of the brain water content in the left and 
right hemispheres (filled/dashed and gray columns, respectively) 
in sham-operated animals, control ischemic rats, and ischemic 
rats that received candesartan (0.3 mg/kg). Asterisk indicates 
significant difference (P < 0.05) from the control group; cross 
indicates significant difference (P < 0.05) from the sham group.
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AT1 receptors. Since these receptors contribute 
to stroke-related pathophysiologic mechanisms, 
such as hypertension, atherothrombosis, and 
cardiac hypertrophy [23], it is possible that Ang II 
aggravates I/R injuries through stimulation of 
AT1 receptors. Previous studies showed that pre-
ischemic RAS inhibition provides protective effects 
with respect to ischemic brain injuries [14, 24, 25]. 
Our study was carried out to evaluate the effects of 
post-ischemic candesartan treatment on ischemic 
brain injuries and edema formation. Candesartan 
freely crosses the blood-brain barrier and produces 
an effective and long-lasting blockade of cerebral 
AT1 receptors [4, 26].
The results of our study demonstrate that blocking 
of AT1 receptors significantly reduces the cortical and 
striatal infarct volumes and improves neurological 
motor deficits. This study also shows that transient 
ischemia induces brain edema by increasing the 
water content in the ischemic hemisphere, while 
post-ischemic candesartan treatment significantly 
reduces the water content in the above hemisphere 
and prevents edema formation. These findings are 
in agreement with reports of other investigators 
demonstrating that blocking of AT1 receptors 
with candesartan reduced the infarct size evoked 
by transient cerebral ischemia in hypertensive 
rats [27, 28]. 
Various mechanisms might be responsible for 
the beneficial effects of the AT1 receptor blockade 
in brain ischemia. Such effects might be partly 
attributed to the stabilizing action on the impaired 
cerebrovascular autoregulation within the penumbra 
[29-31]. In addition, anti-apoptotic mechanisms 
may enhance the protective effects of blocking of 
AT1 receptors [32]. Furthermore, the beneficial 
effects of the AT1 blockade might also be attributed 
to a reduction in the production of ROSs [33].
Cerebral ischemia is associated with excessive 
production of ROSs, especially of superoxide [34]. 
The production of ROSs initiates chain reactions, 
causing damage of cellular macromolecules and 
promoting the mitochondrial apoptosis pathway, 
which ultimately leads to cell death [35]. Our study 
showed that candesartan inhibits ROS generation, 
increases glutathione production, and reduces 
MDA production. These findings are in agreement 
with other reports that showed that activation of 
AT1 receptors results in the intense production of 
superoxide, whereas blockade of these receptors 
is associated with reductions in the amounts of 
superoxide [33]and peroxynitrite [36]. 
The findings of our study also indicated that 
inhibition of RAS by blocking AT1 receptors 
reduces ischemic edema formation. Recent evidence 
suggests that Ang II may be an important stimulus 
for the production of superoxide and peroxynitrite 
in blood vessels [36]. Oxygen-derived free radicals 
are known to increase the permeability of the 
blood-brain barrier [37]. Our results showed that 
candesartan treatment suppresses lipid peroxidation 
and increases the endogenous antioxidant defense 
capacity. Thus, blocking of AT1 receptors may 
reduce ischemic edema via protective effects on 
the blood-brain barrier integrity by reduction of the 
ROS production. 
Therefore, inhibition of RAS by the AT1 receptor 
blocker candesartan noticeably reduces the cerebral 
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Fig. 4. Concentration of malondialdehyde (nmol/mg brain wet 
tissue) in sham-operated animals, control ischemic rats, and 
ischemic rats that received candesartan at the beginning of 
reperfusion. Asterisk indicates significant difference (P < 0.05) 
from control ischemic rats; cross indicates significant difference 
(P < 0.01) from sham-operated rats. 
Fig. 5. Concentration of reduced glutatione (mmol/mg brain 
wet tissue) in sham-operated animals, control ischemic rats, and 
ischemic rats that received candesartan. Other designations are 
the same as in Fig. 4. 
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infarction volume and edema formation in rats 
exposed to transient MCA occlusion. The respective 
mechanisms may be attributed to inhibition of 
lipid peroxidation and increase in the endogenous 
antioxidant capacity.
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